Solution Biologics Sdnbhdsolbio Has Entered Into A Market Authorisation Manufacturing And Commercialisation Agreement With Cansino Biologics Inc Based In Tianjinchina Cansinobio Shse 688185Hkex 06185For The Supply Of Vaccines Especially The Covid 19 Vaccine Into Malaysiaas Part Of The Manufacturing Agreement Solbio Is In The Process Of Establishing A Fill & Finish Facility In Our Current Building At Technology Park Malaysiawe Are Also Responsible To Market The Vaccineco Developed By Cansinobio And The Beijing Institute Of Biotechnologyacademy Of Military Medical Sciencesbib To The Asean Countries Namely Philippines Thailandsingaporemyanmar Vietnam Cambodia Laos And Bruneibiologics And Vaccines Represent One Of The Fastest Growing Classes Of Therapeutic Molecules In Modern Healthcarethe Annual Global Biologics Market Is Expected To Be Approximately Usd 380 Billion By 2024Representing A Relatively Higher Growth Rate~8 Compared To Conventional Pharmaceuticalscurrentlymore Than 350 Biologics Are Commercially Presented In The Biopharmaceuticals Market In The Area Of Vaccinesthere S No Doubt That Immunization Saves Millions Of Lives Every Year From Vaccine Preventable Diseases And One Of The Success Stories In Global Healthmore Than 20 Life Threatening Diseases Can Now Be Prevented By Immunizationand New Vaccines For Major Killers Like Meningitiscervical Cancercholera And Influenza Are Now Being Introduced In Many Countriestodayvaccination Is Increasingly Protecting Health Among People Of All Ages With The Incorporation Of Solution Biologics Sdnbhd As A Biopharmaceutical Companysgb Will Enter Into The Life Sciences Business And Will Work To Deliver Vaccines And Biologics That Will Help Millions In Malaysia And The Asean Region
